These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

424 related articles for article (PubMed ID: 27154396)

  • 61. Cholinesterase inhibitors and memantine for the treatment of Alzheimer and non-Alzheimer dementias.
    Balázs N; Bereczki D; Kovács T
    Ideggyogy Sz; 2021 Nov; 74(11-12):379-387. PubMed ID: 34856086
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Deprescribing cholinesterase inhibitors and memantine in dementia: guideline summary.
    Reeve E; Farrell B; Thompson W; Herrmann N; Sketris I; Magin PJ; Chenoweth L; Gorman M; Quirke L; Bethune G; Hilmer SN
    Med J Aust; 2019 Mar; 210(4):174-179. PubMed ID: 30771226
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Patterns and determinants of dementia pharmacotherapy in a population-based cohort of home care clients.
    Maxwell CJ; Vu M; Hogan DB; Patten SB; Jantzi M; Kergoat MJ; Jetté N; Bronskill SE; Heckman G; Hirdes JP
    Drugs Aging; 2013 Jul; 30(7):569-85. PubMed ID: 23605786
    [TBL] [Abstract][Full Text] [Related]  

  • 64. [Retrospective comparative analysis of antidementia medication persistence patterns in Spanish Alzheimer's disease patients treated with donepezil, rivastigmine, galantamine and memantine].
    Sicras-Mainar A; Vergara J; Leon-Colombo T; Febrer L; Rejas-Gutierrez J
    Rev Neurol; 2006 Oct 16-31; 43(8):449-53. PubMed ID: 17033976
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Anti-Alzheimer drugs: life-threatening adverse effects.
    Prescrire Int; 2007 Feb; 16(87):16. PubMed ID: 17326275
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Cholinesterase inhibitors and memantine have a role in the treatment of Alzheimer's disease.
    Rabins PV; Lyketsos CG
    Nat Clin Pract Neurol; 2006 Nov; 2(11):578-9. PubMed ID: 17057739
    [No Abstract]   [Full Text] [Related]  

  • 67. [Diagnostic guideline and treatment of dementia].
    Olde Rikkert MG; van Exel E; Knol W; Lemstra AW; Roks G; Verhey FR
    Ned Tijdschr Geneeskd; 2015; 159():A8671. PubMed ID: 25873222
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Antidementia drug prescription sources and patterns after the diagnosis of dementia in Germany: results of a claims data-based 1-year follow-up.
    van den Bussche H; Kaduszkiewicz H; Koller D; Eisele M; Steinmann S; Glaeske G; Wiese B
    Int Clin Psychopharmacol; 2011 Jul; 26(4):225-31. PubMed ID: 21394033
    [TBL] [Abstract][Full Text] [Related]  

  • 69. I remember.
    Ladouceur R
    Can Fam Physician; 2006 Feb; 52():155. PubMed ID: 16529383
    [No Abstract]   [Full Text] [Related]  

  • 70. Rationale for combination therapy with galantamine and memantine in Alzheimer's disease.
    Grossberg GT; Edwards KR; Zhao Q
    J Clin Pharmacol; 2006 Jul; 46(7 Suppl 1):17S-26S. PubMed ID: 16809811
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Use of Anti-Dementia Drugs in Relation to Change in Cognition, Behavior, and Functioning in Alzheimer's Disease over a Three-Year Period: Kuopio ALSOVA Study.
    Törmälehto SM; Martikainen JA; Väätäinen ST; Hallikainen IT; Hallikainen M; Bell JS; Koivisto AM
    J Alzheimers Dis; 2015; 48(4):1033-41. PubMed ID: 26444756
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Use of drug treatments for Alzheimer's disease in France: a study on a national level based on the National Alzheimer's Data Bank (Banque Nationale Alzheimer).
    Tifratene K; Duff FL; Pradier C; Quetel J; Lafay P; Schück S; Benzenine E; Quantin C; Robert P
    Pharmacoepidemiol Drug Saf; 2012 Sep; 21(9):1005-12. PubMed ID: 22718684
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Effectiveness of antidementia drugs in delaying Alzheimer's disease progression.
    Rountree SD; Atri A; Lopez OL; Doody RS
    Alzheimers Dement; 2013 May; 9(3):338-45. PubMed ID: 23102979
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Current issues in dementia pharmacotherapy.
    Daiello LA
    Am J Manag Care; 2007 Dec; 13 Suppl 8():S198-202. PubMed ID: 18095783
    [TBL] [Abstract][Full Text] [Related]  

  • 75. [Pharmacological and non-pharmacological treatment of Alzheimer's dementia].
    Wallesch CW
    MMW Fortschr Med; 2013 May; 155(8):60-2. PubMed ID: 24437141
    [No Abstract]   [Full Text] [Related]  

  • 76. Current approaches to the pharmacological treatment of Alzheimer's disease.
    Tan EC; Hilmer SN; Garcia-Ptacek S; Bell JS
    Aust J Gen Pract; 2018 Sep; 47(9):586-592. PubMed ID: 30244564
    [TBL] [Abstract][Full Text] [Related]  

  • 77. [Drug therapy of Alzheimer dementia].
    Skausig OB; Laugesem LP; Jensen T
    Ugeskr Laeger; 2003 Jul; 165(29):2899; author reply 2899-900. PubMed ID: 12908363
    [No Abstract]   [Full Text] [Related]  

  • 78. Anti-dementia drugs and changes in gait: a pre-post quasi-experimental pilot study.
    Beauchet O; Launay CP; Allali G; Watfa G; Gallouj K; Herrmann FR; Annweiler C
    BMC Neurol; 2013 Nov; 13():184. PubMed ID: 24261605
    [TBL] [Abstract][Full Text] [Related]  

  • 79. [Aspects of the report of the IQWiG (Institute for Quality and Cost Effectiveness in Public Health) " Cholinesterase inhibitors in Alzheimer's dementia"].
    Gogol M; Lüttje D; Werner H
    Z Gerontol Geriatr; 2007 Jun; 40(3):192-4. PubMed ID: 17565437
    [No Abstract]   [Full Text] [Related]  

  • 80. Therapeutic advances and risk factor management: our best chance to tackle dementia?
    Chong TW; Loi SM; Lautenschlager NT; Ames D
    Med J Aust; 2016 Feb; 204(3):91-2, 91.e1. PubMed ID: 26866537
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.